Santarus/Pharming HAE drug Ruconest under review at FDA
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review the biologic license application (BLA) for Ruconest (recombinant human C1 esterase inhibitor) as a treatment for acute angioedema attacks in patients with hereditary angioedema (HAE), development partners Santarus and Pharming revealed on 18 June.